FDA Drug Approval and Action Monitor: Approvals, Indications and Priority Reviews

Turn one or more company names into a clean, impact-scored feed of FDA drug approval events from the official openFDA Drugs@FDA API. This Actor monitors FDA drug approval activity per company and classifies each regulatory action: new drug approvals, new indications, priority reviews and other supplements. Instead of a raw application dump, you get the catalyst signal: every event is typed, scored 0 to 100 by potential market impact, ranked most-recent-first, and linked back to its Drugs@FDA record.

A new drug approval or a priority-review efficacy supplement can re-rate a biotech or pharma stock in a single session. This FDA drug approval monitor surfaces those regulatory actions for the companies on your watchlist in one structured dataset.

Why this is different

Most openFDA scrapers hand you raw Drugs@FDA application records and leave the interpretation to you. This Actor adds a classification and scoring layer on top of the same official data:

• Event classification - each submission is labeled as a new drug approval (original NDA/BLA), a new indication or efficacy supplement, a labeling supplement, or another regulatory action.
• Priority-review flag - submissions marked PRIORITY by the FDA are scored above standard reviews.
• Impact score (0 to 100) - event type plus recency are combined into a single, transparent number so high-signal actions float to the top.
• Most-recent-first ranking - the latest actions surface first, then highest impact.
• Verifiable - every event links to its Drugs@FDA record and includes direct FDA document links where available.

Be clear on scope: this is a monitor of regulatory actions already taken (approvals, supplements, status changes that are now in the public record). It is not a forward-looking PDUFA calendar and does not predict upcoming decision dates. Those target dates are not published in a single official openFDA feed.

Who it's for

• Biotech and pharma traders and investors - a ready-made FDA-catalyst dataset for research, screening and monitoring rather than manual searches.
• Fintech and research apps - drop classified regulatory events directly into your own product or model.
• Competitive-intelligence teams - track a competitor's approvals, new indications and pipeline actions over time.

Use cases

• Watchlist monitoring - scan a list of drug sponsors on a schedule and flag any new high-impact approval or supplement.
• Catalyst research - pull a company's recent regulatory actions, sorted by impact.
• Screening - set a minimum impact score to keep only the most material events across many companies.
• Competitive tracking - follow a rival's new indications and labeling changes as they hit the public record.
• Data enrichment - feed structured FDA approval events into dashboards or downstream models.

Input

Field	Type	Required	Description
companies	array	Yes	One or more drug-sponsor company names (for example Pfizer, Vertex, Eli Lilly). Each is scanned in Drugs@FDA. Vaccines and biologics handled by FDA CBER are not in this CDER dataset.
maxEvents	integer	No	How many of the company's most recent regulatory events to classify and rank. Default 25, range 1 to 100.
minImpact	integer	No	Only return events at or above this impact score (for example 70 keeps high-impact events only). Default 0 returns all. Range 0 to 100.

Output

One dataset item per company. Each item holds the original query, summary counts, and a ranked list of classified events.

{
  "type": "fda_events",
  "company_query": "Vertex",
  "events_found": 12,
  "approvals_count": 4,
  "high_impact_count": 5,
  "events": [
    {
      "sponsor": "VERTEX PHARMACEUTICALS INCORPORATED",
      "application_number": "NDA207925",
      "brand_name": "TRIKAFTA",
      "active_ingredient": "ELEXACAFTOR; IVACAFTOR; TEZACAFTOR",
      "submission_type": "SUPPL",
      "submission_class": "Efficacy",
      "review_priority": "PRIORITY",
      "status": "Approved",
      "status_date": "2024-02-08",
      "catalyst": "TRIKAFTA: New indication / efficacy supplement (priority review)",
      "impact": 80,
      "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207925",
      "docs": ["https://www.accessdata.fda.gov/drugsatfda_docs/..."]
    }
  ]
}

Field notes: submission_type is ORIG (original application) or SUPPL (supplement). status is a readable label such as Approved, Tentative approval or Withdrawn. docs holds up to three FDA document links. approvals_count counts ORIG applications; high_impact_count counts events scoring 70 or above.

How the impact score works

The score is computed directly in code from event type, review priority, status and recency, then clamped to the 0 to 100 range:

• Base by event type - original approval (ORIG) starts at 80; a new indication or efficacy supplement (efficacy, indication, Type 6 or Type 8 classes) at 55; a labeling supplement at 30; any other supplement or regulatory action at 35.
• Priority review - adds 10 when the submission is marked PRIORITY.
• Status adjustments - a tentative approval is reduced by 25 (floored at 15); a withdrawn application is set to 20 and relabeled.
• Recency - adds 15 if the status date is within the last 365 days, or 8 if within the last 730 days.

So a recent original approval under priority review scores near the top, while a routine, older labeling supplement scores low. The full ranking is most-recent-first, then by impact.

Use with AI agents and automation

This Actor is built to be called programmatically, not just clicked. You can run it from agent and automation stacks including:

• AI agent frameworks - call it as a tool from LangChain or LlamaIndex pipelines.
• Apify MCP server - expose it to MCP-capable assistants such as Claude, ChatGPT and Cursor so an agent can fetch FDA approval events on demand.
• No-code automation - trigger it from Zapier or Make and route results into sheets, alerts or CRMs.
• Webhooks and schedules - run on a fixed schedule or on demand, and post completed datasets to your own webhook endpoint.

Output is plain JSON, so it slots into existing data flows.

Pricing

Pay-per-event, charged per company analyzed. There is no subscription. Scanning a 10-company watchlist is 10 charges; you pay only for the companies you actually scan.

Data source and compliance

All data comes from the official openFDA Drugs@FDA API (api.fda.gov), a free and public US government data source served as JSON with no API key required. The Actor reads only published regulatory records: applications, submissions, statuses and document links. It collects no personal data. Coverage is FDA CDER drug applications in Drugs@FDA (small molecules and many biologics); vaccines and some biologics handled by CBER are out of scope.

FAQ

What counts as a high-impact event? A new drug approval (original NDA/BLA) and priority-review efficacy or new-indication supplements score highest; routine labeling supplements score low. High-impact is defined as a score of 70 or above.

Which companies can I track? Any drug sponsor in Drugs@FDA. Enter the company name; a wildcard fallback on the first word handles legal-name variations, so "Vertex" matches "VERTEX PHARMACEUTICALS INCORPORATED".

How current is the data? openFDA mirrors the official Drugs@FDA database, and each run reads the latest available data.

Can an AI agent call this automatically? Yes. The Actor is available through the Apify MCP server, so MCP-capable agents like Claude, ChatGPT and Cursor can invoke it directly, and it also works as a tool in LangChain or LlamaIndex.

Does it predict upcoming PDUFA dates? No. It reports regulatory actions already taken and recorded in Drugs@FDA. Forward-looking PDUFA target dates are not part of this dataset.

Why did a company return no results? The name may not match a CDER sponsor in Drugs@FDA, or its products may be CBER vaccines or biologics, which are not in this dataset. Try the registered legal name.

---

Keywords: FDA drug approval, openFDA, Drugs@FDA, drug approvals monitor, regulatory actions, priority review, new drug application, NDA, BLA, new indication, efficacy supplement, pharma regulatory data, biotech catalyst, FDA approval API.

---

Disclaimer: Provided as data for research and monitoring, not investment advice. Historical patterns do not guarantee future results.